Live Report from ASH:
Oblimersen Extends Survival in Chronic Lymphocytic Leukemia

AudioMedica News
AudioMedica News
Live Report from ASH:
Oblimersen Extends Survival in Chronic Lymphocytic Leukemia
Loading
/
Susan O’Brien
Susan O’Brien

SUSAN O’BRIEN, MD Anderson Cancer Center, Houston
For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. Susan O’Brien presented data from this phase III trial to the American Society of Hematology meeting in Atlanta. Sarah Maxwell reports.

Live Report from ASH:<br />Oblimersen Extends Survival in Chronic Lymphocytic Leukemia



LISTEN

[audio:https://www.audiomedica.com/podcasting/oncology/071209_susan_o_brien.mp3]

Further reading

Sign up for AudioMedica.com news

* = required field
Speciality